5年以上白色念珠菌引起的血液感染对唑类抗真菌药的敏感性分析:一项前瞻性观察研究

IF 1.4 Q4 MYCOLOGY
Megha Sharma, Raees Ahmad, Anup K. Ghosh, S. Rudramurthy, A. Chakrabarti
{"title":"5年以上白色念珠菌引起的血液感染对唑类抗真菌药的敏感性分析:一项前瞻性观察研究","authors":"Megha Sharma, Raees Ahmad, Anup K. Ghosh, S. Rudramurthy, A. Chakrabarti","doi":"10.1093/mmy/myac072.P018","DOIUrl":null,"url":null,"abstract":"Abstract Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM Objectives To study the drug susceptibility profile of Candida albicans isolated from bloodstream infection (BSI) against azole anti-fungal agents (fluconazole, itraconazole, voriconazole, and posaconazole) in a tertiary care hospital over 5 years. Methods All blood culture bottles from patients attending our tertiary care hospital between January 2017 to December 2021 and growing Candida albicans were included in the analysis. All blood culture bottles were continuously monitored automatically inside BACTEC 9240 (BD Becton Dickinson, USA). Beep-positive bottles were further processed by preparation of Gram stain smears, sub-culture onto 5% sheep blood agar and MacConkey agar and spot inoculation onto Sabouraud's Dextrose agar (SDA). Isolates were identified as C. albicans using MALDI-TOF MS (Bruker Daltoniks, Bremen, Germany). Broth microdilution (BMD) was performed to determine minimum inhibitory concentration (MIC) of fluconazole, itraconazole, voriconazole, and posaconazole, in accordance with CLSI document M27-A3 and CLSI M27-S4. Representative isolates were further processed to determine the genetic basis of azole resistance (results will be shared at the conference). Results A total of 889 C. albicans were isolated from BSI over 5 years. The rates of resistant were 0.9%, 4.3%, and 1.4%; and that of susceptible dose dependent were 0.8%, 28.5%, and 0.4% for fluconazole, itraconazole, and voriconazole respectively (Fig. 1). The MIC90 of the isolates to fluconazole, itraconazole, voriconazole, and posaconazole were 2 μg/ml, 0.25 μg/ml, 0.5 μg/ml and 0.25 μg/ml, respectively (Fig. 2). Conclusion Azole antifungals continue to retain favorable MIC90 against C. albicans BSI isolates. Flucanozole continues to be the favored drug of choice due to low side-effects, cost-effectiveness, and least resistant rates.","PeriodicalId":18325,"journal":{"name":"Medical mycology journal","volume":"10 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"P018 Susceptibility profile of Candida albicans causing bloodstream infections against azole antifungals over 5 years: A prospective observational study\",\"authors\":\"Megha Sharma, Raees Ahmad, Anup K. Ghosh, S. Rudramurthy, A. Chakrabarti\",\"doi\":\"10.1093/mmy/myac072.P018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM Objectives To study the drug susceptibility profile of Candida albicans isolated from bloodstream infection (BSI) against azole anti-fungal agents (fluconazole, itraconazole, voriconazole, and posaconazole) in a tertiary care hospital over 5 years. Methods All blood culture bottles from patients attending our tertiary care hospital between January 2017 to December 2021 and growing Candida albicans were included in the analysis. All blood culture bottles were continuously monitored automatically inside BACTEC 9240 (BD Becton Dickinson, USA). Beep-positive bottles were further processed by preparation of Gram stain smears, sub-culture onto 5% sheep blood agar and MacConkey agar and spot inoculation onto Sabouraud's Dextrose agar (SDA). Isolates were identified as C. albicans using MALDI-TOF MS (Bruker Daltoniks, Bremen, Germany). Broth microdilution (BMD) was performed to determine minimum inhibitory concentration (MIC) of fluconazole, itraconazole, voriconazole, and posaconazole, in accordance with CLSI document M27-A3 and CLSI M27-S4. Representative isolates were further processed to determine the genetic basis of azole resistance (results will be shared at the conference). Results A total of 889 C. albicans were isolated from BSI over 5 years. The rates of resistant were 0.9%, 4.3%, and 1.4%; and that of susceptible dose dependent were 0.8%, 28.5%, and 0.4% for fluconazole, itraconazole, and voriconazole respectively (Fig. 1). The MIC90 of the isolates to fluconazole, itraconazole, voriconazole, and posaconazole were 2 μg/ml, 0.25 μg/ml, 0.5 μg/ml and 0.25 μg/ml, respectively (Fig. 2). Conclusion Azole antifungals continue to retain favorable MIC90 against C. albicans BSI isolates. Flucanozole continues to be the favored drug of choice due to low side-effects, cost-effectiveness, and least resistant rates.\",\"PeriodicalId\":18325,\"journal\":{\"name\":\"Medical mycology journal\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical mycology journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/mmy/myac072.P018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MYCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/mmy/myac072.P018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MYCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的研究某三级医院血液感染分离的白色念珠菌(BSI)对氟康唑、伊曲康唑、伏立康唑和泊沙康唑5年的药物敏感性。方法选取2017年1月至2021年12月在我院三级医院就诊的所有白色念珠菌生长患者的血培养瓶进行分析。所有血培养瓶均在BACTEC 9240 (BD Becton Dickinson, USA)内自动连续监测。beep阳性瓶的进一步处理方法是制备革兰氏染色涂片,在5%羊血琼脂和麦康基琼脂上继代培养,并在Sabouraud’s Dextrose琼脂(SDA)上点接种。分离株经MALDI-TOF质谱鉴定为白色念珠菌(Bruker Daltoniks, Bremen, Germany)。采用微量肉汤稀释法(BMD)测定氟康唑、伊曲康唑、伏立康唑和泊沙康唑的最低抑菌浓度(MIC),方法与CLSI文献M27-A3和CLSI文献M27-S4一致。对代表性分离株进行进一步处理,以确定唑抗性的遗传基础(结果将在会议上分享)。结果5年间从BSI分离到白色念珠菌889株。耐药率分别为0.9%、4.3%和1.4%;氟康唑、伊曲康唑和伏立康唑的敏感剂量依赖性分别为0.8%、28.5%和0.4%(图1)。菌株对氟康唑、伊曲康唑、伏立康唑和泊沙康唑的MIC90分别为2、0.25、0.5和0.25 μg/ml(图2)。结论唑类抗真菌药物对白色念珠菌BSI分离株的MIC90继续保持良好的水平。氟康唑因其副作用低、成本效益好、耐药率低而继续成为首选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
P018 Susceptibility profile of Candida albicans causing bloodstream infections against azole antifungals over 5 years: A prospective observational study
Abstract Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM Objectives To study the drug susceptibility profile of Candida albicans isolated from bloodstream infection (BSI) against azole anti-fungal agents (fluconazole, itraconazole, voriconazole, and posaconazole) in a tertiary care hospital over 5 years. Methods All blood culture bottles from patients attending our tertiary care hospital between January 2017 to December 2021 and growing Candida albicans were included in the analysis. All blood culture bottles were continuously monitored automatically inside BACTEC 9240 (BD Becton Dickinson, USA). Beep-positive bottles were further processed by preparation of Gram stain smears, sub-culture onto 5% sheep blood agar and MacConkey agar and spot inoculation onto Sabouraud's Dextrose agar (SDA). Isolates were identified as C. albicans using MALDI-TOF MS (Bruker Daltoniks, Bremen, Germany). Broth microdilution (BMD) was performed to determine minimum inhibitory concentration (MIC) of fluconazole, itraconazole, voriconazole, and posaconazole, in accordance with CLSI document M27-A3 and CLSI M27-S4. Representative isolates were further processed to determine the genetic basis of azole resistance (results will be shared at the conference). Results A total of 889 C. albicans were isolated from BSI over 5 years. The rates of resistant were 0.9%, 4.3%, and 1.4%; and that of susceptible dose dependent were 0.8%, 28.5%, and 0.4% for fluconazole, itraconazole, and voriconazole respectively (Fig. 1). The MIC90 of the isolates to fluconazole, itraconazole, voriconazole, and posaconazole were 2 μg/ml, 0.25 μg/ml, 0.5 μg/ml and 0.25 μg/ml, respectively (Fig. 2). Conclusion Azole antifungals continue to retain favorable MIC90 against C. albicans BSI isolates. Flucanozole continues to be the favored drug of choice due to low side-effects, cost-effectiveness, and least resistant rates.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical mycology journal
Medical mycology journal Medicine-Infectious Diseases
CiteScore
1.80
自引率
10.00%
发文量
16
期刊介绍: The Medical Mycology Journal is published by and is the official organ of the Japanese Society for Medical Mycology. The Journal publishes original papers, reviews, and brief reports on topics related to medical and veterinary mycology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信